Cullinan Management (CGEM)
NASDAQ:CGEM
Want to see CGEM full AI Analyst Report?
CGEM Stock Chart & Stats
$15.06
-$0.28(-2.38%)
At close: 4:00 PM EST
$15.06
-$0.28(-2.38%)
Day’s Range― - ―
52-Week Range$5.68 - $16.74
Previous CloseN/A
Volume73.34K
Average Volume (3M)795.18K
Market Cap
$789.65M
Enterprise Value$692.11M
Total Cash (Recent Filing)$377.90M
Total Debt (Recent Filing)$2.68M
Price to Earnings (P/E)―
Beta0.70
Next Earnings
May 07, 2026EPS Estimate
-0.84Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.77
Shares Outstanding60,526,127
10 Day Avg. Volume731,245
30 Day Avg. Volume795,184
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)1.50
Price to Sales (P/S)0.00
P/FCF Ratio-3.48
Enterprise Value/Market Cap0.88
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-4.47K
Enterprise Value/Ebitda-2.86
Forecast
1Y Price Target
$31.67Price Target Upside110.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-2.91
Revenue Forecast (FY)$29.10M
Bulls Say, Bears Say
Bulls Say
CLN-049 Efficacy In Acute Myeloid LeukemiaEarly CLN-049 results showing meaningful response rates and durable remissions in difficult acute myeloid leukemia subtypes could establish a differentiated therapy with potential first‑or best‑in‑class positioning.
CLN-978 Clinical ReadoutsInitial clinical data for CLN-978 in autoimmune diseases could demonstrate tissue B‑cell depletion and an acceptable tolerability profile, providing proof of concept that supports expansion into lupus and rheumatoid arthritis indications.
Intellectual Property ProtectionIssuance of a composition of matter patent for CLN-978 extends intellectual property protection and strengthens the commercial exclusivity outlook for the lead autoimmune program.
Bears Say
Clinical Outcome UncertaintyAdvancement of key programs relies on dose escalation and upcoming trial readouts, so unfavorable safety, efficacy, or durability data at higher doses could materially weaken the company's valuation.
Dosing And Efficacy RiskManagement's expectation that a single non‑optimized dose will not produce a full immune reset implies that multiple or optimized dosing may be required, increasing development complexity and regulatory uncertainty.
Financial And Investor PressureNegative return on equity, weak profitability, and shares trading below the level set by a recent equity offering create valuation pressure and raise the risk of investor impatience amid a multi‑year development timeline.
Cullinan Management News
CGEM FAQ
What was Cullinan Management’s price range in the past 12 months?
Cullinan Management lowest stock price was $5.68 and its highest was $16.74 in the past 12 months.
What is Cullinan Management’s market cap?
Cullinan Management’s market cap is $789.65M.
When is Cullinan Management’s upcoming earnings report date?
Cullinan Management’s upcoming earnings report date is May 07, 2026 which is in 6 days.
How were Cullinan Management’s earnings last quarter?
Cullinan Management released its earnings results on Mar 10, 2026. The company reported -$0.77 earnings per share for the quarter, beating the consensus estimate of -$0.809 by $0.039.
Is Cullinan Management overvalued?
According to Wall Street analysts Cullinan Management’s price is currently Undervalued.
Does Cullinan Management pay dividends?
Cullinan Management does not currently pay dividends.
What is Cullinan Management’s EPS estimate?
Cullinan Management’s EPS estimate is -0.84.
How many shares outstanding does Cullinan Management have?
Cullinan Management has 60,526,127 shares outstanding.
What happened to Cullinan Management’s price movement after its last earnings report?
Cullinan Management reported an EPS of -$0.77 in its last earnings report, beating expectations of -$0.809. Following the earnings report the stock price went down -2.613%.
Which hedge fund is a major shareholder of Cullinan Management?
Currently, no hedge funds are holding shares in CGEM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cullinan Management Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$31.67 (110.27% Upside)
$31.67 (110.27% Upside)
Blogger Sentiment
Bullish
CGEM Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 2.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $772.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 6.0%
Last 30 Days ▼ 6.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
90.87%
12-Months-Change
Fundamentals
Return on Equity
-46.19%
Trailing 12-Months
Asset Growth
-27.84%
Trailing 12-Months
Company Description
Cullinan Management
Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.
CGEM Stock 12 Month Forecast
Average Price Target
$31.67
▲(110.27% Upside)
Technical Analysis
Ownership Overview
16.76% Insiders
9.09% Mutual Funds
0.60% Other Institutional Investors
57.58% Public Companies and Individual Investors